Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions

Malignant Neoplasms of Female Genital OrgansOvarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Interventions

DRUG

Bevacizumab

15 mg/kg by vein on Day 1 of every 21-day study cycle.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02884648 - Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery | Biotech Hunter | Biotech Hunter